fda compounding semaglutide warning letters october 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications. Read more at the link in the comments below FDA Sends Warning Letters to

Try walking, swimming, cycling, or fitness classes

The fast losers are typically younger, have more weight to lose, started at higher body fat percentages, and often aren't training (meaning they're not preserving muscle, which makes the scale drop faster but the long-term outcome worse)

The review also notes that GLP-1 medicines reduce complications in conditions such as obstructive sleep apnea (OSA), expanding their cardiometabolic relevance

Laboratory and Analytical Context In professional research environments, synthetic peptide reference compounds such as AOD-9604 may be incorporated into structured and controlled workflows that emphasize analytical rigor and traceability

FOR LABORATORY RESEARCH USE ONLY